Promising treatment results of adjuvant chemotherapy following radical hysterectomy for intermediate risk stage 1B cervical cancer
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Objective The aim of this retrospective study is to evaluate the efficacy of adjuvant chemotherapy following radical hysterectomy for intermediate risk stage IB cervical cancer. Methods From January 1993 to December 2007, a total of 100 patients of stage IB were enrolled in this study who had at least two of the following three intermediate risk factors (deep stromal invasion, lymphovascular space involvement, and large tumor size) after radical hysterectomy and all patients had no high risk factors and no radiotherapy. Of these patients, 22 patients had surgery only and 78 patients had cisplatin-based combination chemotherapy as adjuvant therapy postoperatively to improve survival. Kaplan-Meier survival curves and Cox’s proportional-hazards regression model and log-rank test were used for survival analysis and to estimate the impact of prognostic factors on survival. Results The mean age was 52 years (range, 28 to 76 years). The overall survival rate of all intermediate tumors are 92% (92/100). Surgery only group is 81.8% (18/22) and adjuvant chemotherapy group is 94.9% (74/78). Comparison of survival between two groups revealed significant statistical difference in both univariant and multivariant survival analysis (P<0.05). The main toxicities of adjuvant chemotherapy were bone marrow suppression (18%), nausea and vomiting (5.2%) and alopecia in etoposide-cisplatin chemotherapy group (100%) but most side effects of postoperative adjuvant chemotherapy were transient, reversible and within acceptable limits to all patients. Conclusion Cisplatin based combined adjuvant chemotherapy for intermediate risk tumors after radical hysterectomy is promising with significant improvement of overall survival and with acceptable toxicity profile.
Abstract
Objective The aim of this retrospective study is to evaluate the efficacy of adjuvant chemotherapy following radical hysterectomy for intermediate risk stage IB cervical cancer. Methods From January 1993 to December 2007, a total of 100 patients of stage IB were enrolled in this study who had at least two of the following three intermediate risk factors (deep stromal invasion, lymphovascular space involvement, and large tumor size) after radical hysterectomy and all patients had no high risk factors and no radiotherapy. Of these patients, 22 patients had surgery only and 78 patients had cisplatin-based combination chemotherapy as adjuvant therapy postoperatively to improve survival. Kaplan-Meier survival curves and Cox’s proportional-hazards regression model and log-rank test were used for survival analysis and to estimate the impact of prognostic factors on survival. Results The mean age was 52 years (range, 28 to 76 years). The overall survival rate of all intermediate tumors are 92% (92/100). Surgery only group is 81.8% (18/22) and adjuvant chemotherapy group is 94.9% (74/78). Comparison of survival between two groups revealed significant statistical difference in both univariant and multivariant survival analysis (P<0.05). The main toxicities of adjuvant chemotherapy were bone marrow suppression (18%), nausea and vomiting (5.2%) and alopecia in etoposide-cisplatin chemotherapy group (100%) but most side effects of postoperative adjuvant chemotherapy were transient, reversible and within acceptable limits to all patients. Conclusion Cisplatin based combined adjuvant chemotherapy for intermediate risk tumors after radical hysterectomy is promising with significant improvement of overall survival and with acceptable toxicity profile.
참고문헌 (24)
- Hacker NF, "Cervical cancer, In Berek & Hacker’s gynecologic oncology", pp.341~395 (2010), Lippincott Williams & Wilkins
- Bidus MA, "Cervical and vaginal cancer, In Berek & Novak’s gynecology", pp.1403~1456 (2007), Lippincott Williams & Wilkins
- Boyce J, "Prognostic factors in stage I carcinoma of the cervix", Gynecol Oncol, 12, pp.154~165 (1981)
- Delgado G, "A prospective surgical pathological study of stage I squamous carcinoma of the cervix : a Gynecologic Oncology Group Study", Gynecol Oncol, 35, pp.314~320 (1989)
- Delgado G, "Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix : a Gynecologic Oncology Group study", Gynecol Oncol, 38, pp.352~357 (1990)
- Morris M, "Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer", N Engl J Med, 340, pp.1137~1143 (1999)
- Peters WA 3rd, "Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix", J Clin Oncol, 18, pp.1606~1613 (2000)
- Hee-SugRyu, "Concurrent Chemoradiotherapy in Cervical Cancer (A New Paradigm in Cervical Cancer Treatment)", Yonsei Medical Journal, 43(6), pp.749~753 (2002), 연세대학교의과대학
- Sedlis A, "A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy : a Gynecologic Oncology Group Study", Gynecol Oncol, 73, pp.177~183 (1999)
- Soisson AP, "Adjuvant radiotherapy following radical hysterectomy for patients with stage IB and IIA cervical cancer", Gynecol Oncol, 37, pp.390~395 (1990)
- Rotman M, "A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study", Int J Radiat Oncol Biol Phys, 65, pp.169~176 (2006)
- Iwasaka T, "Adjuvant chemotherapy after radical hysterectomy for cervical carcinoma : a comparison with effects of adjuvant radiotherapy", Obstet Gynecol, 91, pp.977~981 (1998)
- Takeshima N, "Treatment results of adjuvant chemotherapy after radical hysterectomy for intermediate-and high-risk stage IB-IIA cervical cancer", Gynecol Oncol, 103, pp.618~622 (2006)
- Tattersall MH, "A randomized trial of adjuvant chemotherapy after radical hysterectomy in stage Ib-IIa cervical cancer patients with pelvic lymph node metastases", Gynecol Oncol, 46, pp.176~181 (1992)
- Alberts DS, "Cisplatin in advanced cancer of the cervix : an update", Semin Oncol, 18, pp.11~24 (1991)
- Runowicz CD, "Concomitant cisplatin and radiotherapy in locally advanced cervical carcinoma", Gynecol Oncol, 34, pp.395~401 (1989)
- Al-Saleh E, "Cisplatin", etoposide chemotherapy for recurrent or primarily advanced cervical carcinoma, 1997, pp.64, 468~472
- Olive ST, "Diagnosis of appendicitis", Am Board Fam Pract, 9, pp.306~307 (1996)
- Bonomi P, "A phase II evaluation of cisplatin and 5-fluorouracil in patients with advanced squamous cell carcinoma of the cervix : a Gynecologic Oncology Group Study", Gynecol Oncol, 34, pp.357~359 (1989)
- Namkoong SE, "Comparative study of the patients with locally advanced stages I and II cervical cancer treated by radical surgery with and without preoperative adjuvant chemotherapy", Gynecol Oncol, 59, pp.136~142 (1995)
- Alberts DS, "Phase II randomized trial of cisplatin chemotherapy regimens in the treatment of recurrent or metastatic squamous cell cancer of the cervix: a Southwest Oncology Group Study", J Clin Oncol, 5, pp.c1791~c1795 (1987)
- Dische S, "Radiotherapy of cervical cancer", Clin Obstet Gynaecol, 12, pp.203~227 (1985)
- Barter JF, "Complications of combined radical hysterectomy-postoperative radiation therapy in women with early stage cervical cancer", Gynecol Oncol, 32, pp.292~296 (1989)
- Markmam M, "Chemotherapy, In Berek & Hacker’s gynecologic oncology", pp.57~82 (2010), Lippincott Williams & Wilkins